Author's posts
Biotech IPO Markets: Closing The Books On 2018’s Crazy Year
2018 was a incredible boom year in the number of new biotech offerings. Author explores the data around post-IPO market performance and the challenging end of year in the stock market.
2018’s Biotech IPO Bonanza: View From the After Market
2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings. The author explores the data around their post-IPO share performance, relative to prior years.
Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
Should newly-minted public biotechs be worried about a flood of stock impairing their stock prices following the post-IPO lockup expiry? The data suggests, in general, this isn’t a real concern: its more urban legend than reality
The Rising Tide Of Biotech IPO Valuations
To frame up how the Biotech IPO markets have evolved over the past six years, the author reviews data around the changes to pre-money valuations over time. The trend line is clear: up and to the right
The Incredible Expanding Universe of Biotech Stocks
The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint.
Biotech Venture Deal Terms Are More “Startup-Friendly” Than Ever
Biotech is booming, and that’s having an impact on deal terms. The author highlights a few observations from the Venture Financing Report of law firm Cooley LLP: money is flowing, valuations are up across the board, and deal terms are “looser” than the…
A Hat Trick Of Cell And Gene Therapy IPOs: AVRO, MGTA, and UMRX
Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three are cell and gene therapy biotechs. The author shares his reflections on those companies, the …
